The THC Heart-Rate Dose Meta-Regression Did Not Provide an Individual Dose Calculator

The cardiovascular review found a relationship between THC dose and human heart-rate effect across studies. That meta-regression did not establish a precise pulse change for a particular person.

The analysis concerned study-level effects

The review reports dose-dependent tachycardia in its human analysis and discusses oral trials using several THC doses. Meta-regression relates dose conditions to estimated effects across the included comparisons. It does not automatically reconstruct the exposure-response curve of an individual participant.

Route and timing also changed the exposure

The authors identify heterogeneity in administration route, dose and assessment time. A labeled dose does not ensure a matching peak concentration across those conditions. Combining the study results therefore cannot supply a single conversion from milligrams of THC to beats per minute for clinical or forensic use.

Pulse is not an impairment measurement

The association does not establish that a larger pulse increase always means greater cognitive impairment, nor that an unchanged pulse excludes a drug effect. Those conclusions require their own functional evidence. The useful contribution is a group-level physiological dose signal within a limited historical evidence base. An accurate account preserves the analysis level and protocol variation rather than turning the result into a personal dosing or last-use estimate.

Related analysis: the study’s broader findings and limitations.

Research cited

Sultan, Millar, O’Sullivan and England (2018). A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ9-Tetrahydrocannabinol.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy. Later treatment histories became mixed The study included different continuation and crossover arrangements across its phases….

Spread the love

Read Article: Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

The chemotherapy study permitted capsule adjustment according to nausea and side effects. Active and placebo participants consequently did not take the same median number of capsules per dose. Capsule content and regimen were specified Each active capsule contained 2.5 milligrams of THC and 2.5 milligrams of CBD. Treatment was scheduled…

Spread the love

Read Article: Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition. The assessments used different frameworks Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for…

Spread the love

Read Article: Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us